A new bone cement was developed with the purpose of reducing the adverse biological effects during cementation of implants. This bone cement is characterized by fewer exotherm, low release of monomer, low residual content of monomer, and retained physical properties. The essential innovation was substitution of half of the methylmethacrylate (MMA) in the monomer with long chain, high molecular weight, less volatile, and less soluble methacrylates (n-decylmethacrylate, isobornyl-methacrylate), as well as alteration of the accelerator system to a mix of dihydroxypropyl-p-toluidine and N,N-dimethyl-p-toluidine. The powder contains butylmethacrylate-MMA copolymers. These measures lower the glass-transition temperature, and permit more complete mixing in an integrated package, mixing, and delivery system consisting of a vacuum packed, double chamber pouch. The porosity was reduced to about 2% and the largest voids measured 0.1 mm. The polymerization exotherm was reduced to 58 degrees C. The compressive strength was 82 MPa, the four-point bending strength 55 MPa, the flexural modulus 2.24 GPa, the tensile strength 32 MPA, and the shear strength 36 MPa. The fracture toughness was 0.89 MPa root cm. These mechanical properties together with the fatigue life were on level with manually mixed, conventional PMMA bone cements. (C) 1995 John Wiley and Sons, Inc.
